VTYX - Ventyx Biosciences Inc
IEX Last Trade
2.24
0.040 1.786%
Share volume: 834,121
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$2.20
0.04
1.82%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.33%
1 Month
-3.04%
3 Months
-53.64%
6 Months
-71.30%
1 Year
-93.31%
2 Year
-89.10%
Key data
Stock price
$2.24
DAY RANGE
$2.05 - N/A
52 WEEK RANGE
$1.79 - $38.20
52 WEEK CHANGE
-$0.93
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Raju S. Mohan
Region: US
Website: ventyxbio.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ventyxbio.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.
Recent news